What it is
TB-500 (Thymosin β-4 Acetate) is a synthetic version of the active region of Thymosin β-4, a naturally occurring 43-amino-acid peptide found in virtually all human cells. It promotes cell migration, reduces inflammation, and stimulates the formation of new blood vessels, accelerating recovery in muscles, tendons, and ligaments. Indirect anti-aging benefits include enhanced healing, decreased inflammation, and improved flexibility — supporting physical resilience and long-term vitality.
Mechanism of action
Thymosin β-4 sequesters G-actin, regulating cytoskeletal dynamics essential for cell motility. It also upregulates VEGF, stimulates endothelial cell migration, and has anti-inflammatory effects via reduced NF-κB activation.
Half-life: Plasma half-life ~2 hours; extended tissue activity due to lipid-binding.
Evidence summary
Demonstrated in preclinical models to accelerate healing of myocardial injury, corneal wounds, and skin. Phase 1/2 human trials have explored it for pressure ulcers and dry eye. No FDA approval for systemic use.
Pantheon dosing guide
- Application
- Subcutaneous injection.
- BAC Water
- 2 mg: 2 ml 5 mg: 2.5 ml
- Dose
- 2 mg: 10 units (100 mcg) to 20 units (200 mcg). 5 mg: 10 units (200 mcg) to 20 units (400 mcg).
- Frequency & Cycle Length
- 5 days on / 2 days off. 4 to 5 weeks.
- Timing
- Take in the morning on an empty stomach, at least 30 minutes before eating.
- Key Benefits
- Accelerates repair of muscles, tendons, and ligaments. Reduces chronic and acute inflammation. Promotes flexibility and mobility. Supports heart and blood vessel health.
Additional research protocol context
The printed guide above is Pantheon's dosing reference. These broader research examples are provided as context and may use different schedules.
- Loading phase: 2–5 mg twice weekly for 4–6 weeks
- Maintenance: 2 mg once weekly for 4–6 weeks
- Wolverine Cycle exception: follow the Wolverine dosing guide instead of standalone TB-500 loading: 300 mcg (15 units) with BPC-157 Monday-Friday mornings, weekends off
Side effects & safety
- Transient fatigue or head-rush in first few injections
- Possible mild redness at injection site
- Limited long-term human safety data
Cited studies
- Malinda KM, Sidhu GS, Mani H, et al. (1999). Thymosin β4 accelerates wound healing. Journal of Investigative Dermatology.PMID 10469330Read source ↗
- Goldstein AL, Hannappel E, Kleinman HK (2005). Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine.PMID 16169269Read source ↗
- Bock-Marquette I, Saxena A, White MD, et al. (2004). Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature.PMID 15525990Read source ↗
- (2007). The peptide thymosin β4 (Tβ4) promotes angiogenesis and wound healing. Annals of the New York Academy of Sciences (ScienceDirect).Read source ↗
- (2021). A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. Frontiers in Pharmacology (NLM).Read source ↗
- Goldstein AL, Kleinman HK (2015). Advances in the basic and clinical applications of thymosin β4. Expert Opinion on Biological Therapy.Read source ↗
- (2015). Potential Role of Thymosin Beta 4 in Liver Fibrosis. International Journal of Molecular Sciences (Pusan National University).Read source ↗
- (2018). Matrigel uses in cell biology and for the identification of thymosin β4, a mediator of tissue regeneration. Heliyon (SpringerOpen).Read source ↗
- (2021). New Directions in Anti-Aging Regenerative Therapies. International Journal of Molecular Sciences (NLM).Read source ↗
All content is for research and educational purposes. Peptides described are sold for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any protocol.